The Centers for Disease Control and Prevention (CDC) recognizes the relationship between Chlamydia pneumoniae and Asthma

An article published by the CDC acknowledges the possible association of C.pneumoniae with Alzheimer’s disease, asthma and reactive arthritis (RA). They also acknowledge using Macrolides type of antibiotics for the treatment.

NOTE:  The article mysteriously disappeared from the CDC website a few months after being published.  Very unfortunate.

Read the published article

Transmission:  Person-to-person transmission by respiratory secretions. Outbreaks can occur periodically, primarily in close-contact settings such as military barracks, college dormitories, long-term care facilities, or prisons.
Treatment: Macrolides are often the first-line treatment; tetracyclines and fluoroquinolones are also effective.
Challenges: There is a lack of standardized diagnostic methods. Isolation of the etiologic agent is difficult, so antibody tests using paired acute- and convalescent-phase sera have been used for diagnosis. There are no known methods to prevent possible sequelae. The role of C. pneumoniae in atherosclerotic vascular disease needs further definition. Postinfection carriage of C.pneumoniae can occur for up to 8 weeks.